Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/CTRI/2021/06/034326
CTRI/2021/06/034326Not yet recruitingPhase 4

TITRATION OF BUPRENORPHINEAND NALOXONE COMBINATIONDOSE IN PATIENTS DEPENDENTON POPPY HUSK: A PROSPECTIVEOPEN LABEL STUDY

ALL INDIA INSTITUTE OF MEDICAL SCIENCES RAIPUR0 sites0 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • •Diagnosed as a patient of opioid dependence as per ICD 10 Diagnostic and clinical
  • •Research criteria for dependence (F11)
  • •-Not On opioid substitution therapy for last 2 months
  • •-Only poppy husk User
  • •-Informed consent for participant

Exclusion Criteria

  • •-Patient dependent on any other substance except Nicotine And Caffeine
  • •- Using opioid in any form other than natural (synthetic, semi synthetic, prescribed
  • •medication etc) for 6 months.
  • •- Patient of other organic brain disorder or of mental retardation and any other psychiatric
  • •- Patient of any unstable medical illness requiring priority management.

Investigators

Similar Trials

Recruiting
Phase 4
to compare combination of Buprenorphine-naloxone with moxonidine versus clonidine in opioid detoxificatio
CTRI/2022/07/043760Govt Medical College Rajindra Hospital Patiala
Not yet recruiting
Not Applicable
To evaluate the efficacy of Buprenorphine and 2%lignocaine with adrenaline 1:80,000 when given as inferior alveolar nerve block in providing post- operative comfort after lower third molar surgery
CTRI/2019/08/021004Dr Sneha Punamiya
Active, not recruiting
Phase 1
Add-on buprenorphine at analgesic doses for the treatment of severe suicidal ideas during a major depressive episodemental disordersMedDRA version: 23.0Level: LLTClassification code: 10083288Term: Clinical depression Class: 10037175
CTIS2024-512445-17-00Centre Hospitalier Universitaire De Nimes180
Active, not recruiting
Phase 1
Add-on buprenorphine for the treatment of severe suicidal ideasTreatment of severe suicidal ideas in patients suffers from a current major depressive episodeMedDRA version: 23.0Level: LLTClassification code 10083288Term: Clinical depressionSystem Organ Class: 100000004873
EUCTR2018-003816-38-FRCHU DE NIMES180
Completed
Early Phase 1
Comparison of naloxone & buprenorphine on reversal of Opioid Overdose Syndrome and withdrawal in Methadone – Dependant Patients; An experimental StudyMethadone Overdose.Poisoning by Methadone
IRCT2015011020624N1Shahid Beheshti University of Medical Sciences90